Author:
Marni Rakshmitha,Malla Manas,Chakraborty Anindita,Voonna Murali Krishna,Bhattacharyya Partha Sarathi,KGK Deepak,Malla Rama Rao
Funder
UGC-DAE-CSR, Kolkata, India
Publisher
Springer Science and Business Media LLC
Reference74 articles.
1. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR (2016) Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine 95(35):e4614
2. Yin L, Duan J-J, Bian X-W, Yu S-c (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22(1):61. https://doi.org/10.1186/s13058-020-01296-5
3. Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15(1):121. https://doi.org/10.1186/s13045-022-01341-0
4. Grozdanovic J, Vích Z, Truxová G (1968) The combined effect of 6-azauridine and irradiation in vivo and in vitro. II. The nucleic acid livel in the ehrlich ascitic carcinoma cells after repeated applications of 6-AzUR and irradiation in vitro. Neoplasma 15(6):685–687
5. Grozdanovic J, Vích Z, Truxová G, Kratochvíl J (1970) Combined effect of 6-azauridine and irradiation in vivo and in vitro. VI. Nuclear diameters of Ehrlich ascites carcinoma cells after repeated irradiation and 6-AzUR application. Neoplasma 17(6):601–606